Scientific Publication

A biometric breakthrough promises to solve crimes faster than ever. But as AI closes cold cases, it opens a Pandora's box of ethical and privacy questions.

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

Endeavor Health's new genetic test provides a "floodlight" on heart disease risk, but with no insurance coverage, who will get to see the light?

A single blood test can now simultaneously track immune response, tumor changes, and resistance, offering new hope for personalizing sarcoma immunotherapy.

A new study on runners reveals how vagus nerve stimulation improves recovery and sleep, pioneering a 'Stress Fitness' approach for athletes.

New preclinical data shows Sharp Therapeutics' oral drug candidate could reverse key pathologies of the fatal genetic disorder, offering hope beyond symptom management.

A landmark study offers reassurance on kids' heart health post-COVID but details a range of persistent symptoms, separating viral effects from pandemic stress.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

Researchers have validated the first tool to measure period product insecurity, a data-driven breakthrough that promises to transform policy and advocacy.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Myers' EnerShed 2.0 is the first BESS to conquer the stringent UL 9540A 6th Edition fire test, a milestone poised to accelerate clean energy adoption.

A new study reveals a sharp drop in prescription fills at just $35, highlighting a critical affordability crisis that even insured patients can't escape.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

NImmune Biopharma's oral drug NIM-1324 shows promising safety and efficacy, targeting a novel pathway to treat IBD and a host of other diseases.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

A new analysis shows AI platforms can cut hospital costs by $2M annually while reducing ICU stays and ventilation time, transforming critical care.